Core Viewpoint - Lepu Biopharma-B (02157) experienced a significant stock increase, rising over 6% in late trading, with a current price of HKD 5.64 and a trading volume of HKD 71.31 million [1] Group 1: Clinical Trial Developments - CG Oncology is set to announce the primary data from the PIVOT-006 Phase 3 clinical trial evaluating the monotherapy of cretostimogene for high-risk non-muscle invasive bladder cancer in the first half of 2026, which is nearly one year ahead of the original schedule due to a much faster-than-expected enrollment rate [1] - Lepu Biopharma holds the rights to CG0070 injection (Cretostimogene Grenadenorepvec) in Greater China and is actively advancing clinical progress domestically while CG Oncology achieves clinical breakthroughs abroad [1] Group 2: Product Synergy - Lepu Biopharma possesses an already marketed PD-1 antibody, Putilizumab, which can complement the treatment of NMIBC when combined with cretostimogene, potentially enhancing therapeutic efficacy [1]

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Lepu Biopharma-B (02157), which rose over 6% and is currently trading at 5.64 HKD with a trading volume of 71.31 million HKD [1] - CG Oncology is expected to announce the primary data from the PIVOT-006 Phase 3 clinical trial for cretostimogene monotherapy in high-risk non-muscle invasive bladder cancer in the first half of 2026, which is nearly a year earlier than originally planned due to a faster-than-expected enrollment rate [1] - Lepu Biopharma has exclusive rights to CG0070 injection (Cretostimogene Grenadenorepvec) in Greater China and is actively advancing clinical progress domestically while CG Oncology achieves clinical breakthroughs abroad [1] Group 2 - Lepu Biopharma possesses an already marketed PD-1 antibody, Putili monoclonal antibody, which can complement the treatment of NMIBC (non-muscle invasive bladder cancer) to enhance efficacy through combination therapy [1]